Low-grade glioma · 4 regimens
Cost vs Efficacy · 2 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Temozolomide monotherapy Variant #13 | — | R 8 153 | 28d | ~39.0 mo | — | ~43 | ~R 350 573 PFS proxy · indirect | 1 |
Carboplatin monotherapy Variant #01 | — | R 1 231 | 21d | ~5.8 mo | ~21.0 mo | ~9 | ~R 11 076 PFS proxy · indirect | 7 |
Carboplatin and Teniposide Variant #01 Partial | — | R 1 061 | 28d | — | — | — | — | — |
PCV Variant #01 Partial | — | R 389 | 42d | — | ~159.6 mo | — | — | 1 |
4 of 4 regimens shown